Uptravi (selexipag) / J&J 
Welcome,         Profile    Billing    Logout  
 17 Diseases   8 Trials   8 Trials   676 News 


«12345678910»
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Clinical, Clinical Trial,Phase II, Journal:  Pharmacological characteristics and clinical study results of Selexipag (Uptravi tablets), a selective prostacyclin receptor agonist (Pubmed Central) -  May 13, 2021   
    In the GRIPHON (Prostacyclin (PGI) Receptor agonist In Pulmonary arterial HypertensiON) study in 1156 patients with PAH, the largest outcome study ever conducted in PAH, the selexipag treatment group showed a significant reduction in the risk of the primary composite endpoint of death or a complication related to PAH compared with placebo. Selexipag has been shown in clinical trials to prevent the progression of PAH, and is expected to contribute to the treatment of patients with PAH.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Journal:  Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. (Pubmed Central) -  May 7, 2021   
    Selexipag has been shown in clinical trials to prevent the progression of PAH, and is expected to contribute to the treatment of patients with PAH. These results support the association between risk profile and long-term outcome and suggest that selexipag treatment may improve risk profile.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Review, Journal:  Selexipag for pulmonary arterial hypertension. (Pubmed Central) -  Apr 30, 2021   
    In this case the patient was rapidly transitioned from oral selexipag to i.v. and then subcutaneous treprostinil therapy over a 30-hour period, with minimal adverse effects. No abstract available
  • ||||||||||  [VIRTUAL] EFFECTS OF FACE-TO-FACE EDUCATIONAL NURSING SUPPORT ON PATIENT COMPLIANCE WITH ORAL PAH THERAPIES () -  Apr 11, 2021 - Abstract #AMCP2021AMCP_128;    
    Patients receiving oral PAH therapies in an educational nursing program demonstrated a positive effect on overall medication compliance as demonstrated by a statistically significant improvement in MPR and therapy persistence. While our study compared two different PAH therapy classes, a multidisciplinary patient support approach contributed to improved patient outcomes.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Trial completion date, Trial primary completion date:  SPHERE: A Registry for Patients Taking Uptravi (clinicaltrials.gov) -  Mar 16, 2021   
    P=N/A,  N=800, Active, not recruiting, 
    While our study compared two different PAH therapy classes, a multidisciplinary patient support approach contributed to improved patient outcomes. Trial completion date: Jun 2022 --> Sep 2021 | Trial primary completion date: Jun 2022 --> Sep 2021
  • ||||||||||  amphetamine / Generic mfg.
    [VIRTUAL] Severe Pulmonary Arterial Hypertension in a Patient with a History of Phenylpropanolamine Use () -  Mar 14, 2021 - Abstract #ATS2021ATS_3152;    
    Phenylpropanolamine is a drug with a similar structure to amphetamine that was withdrawn from the US market in 2000...Also, there is a report of a fatal case of PAH in a child who was treated with high doses of phenylpropanolamine that was contained in cold medicine. While our case does not serve to establish causality, it highlights a possible association for clinicians to consider.
  • ||||||||||  Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen, Uptravi (selexipag) / J&J, Nippon Shinyaku
    [VIRTUAL] Real-World Experience of Selexipag in Patients with Pulmonary Arterial Hypertension in an Irish Center () -  Mar 14, 2021 - Abstract #ATS2021ATS_66;    
    Conclusion This is the first study of real-world experience of selexipag in Ireland and demonstrates that selexipag can be safely initiated, titrated and transitioned in an outpatient setting to achieve an individualised dosing regimen. Close observation and consideration of clinical, biochemical and hemodynamic parameters are recommended following any changes in baseline drug therapy.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    [VIRTUAL] AN ATRIAL SEPTAL DEFECT, EISENMENGER’S AND A BABY; THE CONUNDRUM OF CARE (eAbstract site) -  Feb 17, 2021 - Abstract #ACC2021ACC_7912;    
    Pulmonary vasodilator therapy may improve outcomes for these patients, but, condition may still prove fatal. Multidisciplinary team care at a tertiary center is essential to assure improved survival and overall outcomes.
  • ||||||||||  hydroxychloroquine / Generic mfg.
    [VIRTUAL] CHALLENGES IN THE MANAGEMENT OF MIXED CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY HYPERTENSION AND CARDIOGENIC SHOCK (eAbstract site) -  Feb 17, 2021 - Abstract #ACC2021ACC_4273;    
    A CTA of the abdomen and pelvis demonstrated lymphadenopathy and moderate splenomegaly with associated thrombocytopenia at baseline.Decision‐making: In addition to hydroxychloroquine and standard heart failure therapies (including diuretics, spironolactone, digoxin, and milrinone), combination PAH therapy with sildenafil and IV epoprostenol was initiated. This case highlights the importance of appropriate diagnosis and a multidisciplinary approach to comprehensive management of a patient with clinical manifestations of MCTD complicating the optimization of PAH therapy.
  • ||||||||||  Uptravi (selexipag) / J&J
    Trial primary completion date:  ACT-293987 in Pulmonary Arterial Hypertension (clinicaltrials.gov) -  Jan 22, 2021   
    P3,  N=1187, Active, not recruiting, 
    Please refer to page A240 for declarations of interest related to this abstract. Trial primary completion date: Dec 2020 --> Apr 2021
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Journal:  An evaluation of selexipag for the treatment of pulmonary hypertension. (Pubmed Central) -  Jan 21, 2021   
    Current guidelines do not provide definitive recommendations regarding the place of selexipag in the treatment algorithm of PAH. Finally, the possibility of transition between the several drugs acting in the prostacyclin pathway, and the potential role of selexipag in chronic thromboembolic pulmonary hypertension and pediatric PAH is currently being examined, possibly expanding its future use.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Clinical, Journal:  Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series. (Pubmed Central) -  Jan 15, 2021   
    Selexipag is a promising oral therapy for patients with at various stages of the spectrum of PAH-CHD to improve symptoms, exercise capacity and, in some cases, haemodynamics. Our cases also highlight practical aspects of Selexipag use including targeting the individualized maximally tolerated dose for each patient, managing side effects and managing dose interruptions.
  • ||||||||||  Uptravi Injection (selexipag IV) / J&J, Nippon Shinyaku, Uptravi (selexipag) / J&J, Nippon Shinyaku, Tyvaso (treprostinil) / United Therapeutics
    Retrospective data, Journal, HEOR:  Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis. (Pubmed Central) -  Nov 28, 2020   
    Compared with oral treprostinil, selexipag was associated with a 46% lower risk of all-cause hospitalization (hazard ratio 0.54, 95% confidence interval 0.31, 0.92; P = 0.02), a 47% lower risk of pulmonary hypertension-related hospitalization (hazard ratio 0.53, 95% confidence interval 0.31, 0.93; P = 0.03), a 42% lower all-cause hospitalization rate (rate ratio 0.58, 95% confidence interval 0.39, 0.87; P = 0.01), and a 46% lower pulmonary hypertension-related hospitalization rate (rate ratio 0.54, 95% confidence interval 0.35, 0.82; P = 0.004). This study suggests that selexipag is associated with lower hospitalization risk and rate than oral treprostinil.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku, Opsumit (macitentan) / Nippon Shinyaku, J&J
    Enrollment open:  INSPECTIO: A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag (clinicaltrials.gov) -  Nov 12, 2020   
    P=N/A,  N=200, Recruiting, 
    Given the potential effect seen in our patient, upfront triple oral combination therapy in PAH high-risk patients should be further evaluated in a controlled clinical trial. Not yet recruiting --> Recruiting
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    [VIRTUAL] Decompensated Eisenminger Syndrome In A Multiparturient () -  Oct 17, 2020 - Abstract #ASA2020ASA_1119;    
    She remained hemodynamically stable throughout her delivery and gave birth to a female with Apgar's 9/9. She was discharged on her home medications on POD6.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    [VIRTUAL] ASSESSING DAILY LIFE PHYSICAL ACTIVITY BY ACTIGRAPHY IN PULMONARY ARTERIAL HYPERTENSION: INSIGHTS FROM THE RANDOMIZED CONTROLLED STUDY WITH SELEXIPAG (TRACE) () -  Oct 12, 2020 - Abstract #CHEST2020CHEST_2662;    
    P4
    TRACE is the first randomized trial to successfully collect high quality actigraphy data in PAH and allows for better understanding of DLPA.The population was prevalent, predominantly low risk, established on double background therapy and not actively encouraged to increase activity, potentially limiting the ability to detect short-term improvements.We report no statistically significant differences in DLPA parameters between sel and plc.Changes were small, highly variable, and their clinical relevance is yet to be established. CLINICAL IMPLICATIONS: Actigraphy complements current approaches to understand DLPA in PAH and may be considered a novel endpoint in future trials.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    [VIRTUAL] OVERLAP SYNDROME AND MYELOPEROXIDASE-POSITIVE VASCULITIS: NEW PULMONARY FINDINGS () -  Oct 12, 2020 - Abstract #CHEST2020CHEST_2366;    
    There are 3 hallmark radiologic signs that were recently observed in patients with CTD-ILD in a retrospective analysis from University of Chicago... We report this case to add patients with overlap syndrome and MPO positive vasculitis related ILD to the panel of previously described patients with scleroderma, rheumatoid arthritis, myositis and Sjogren’s disease.